Introduction {#Sec1}
============

Human cells maintain their homeostasis through energy production via glucose catabolism. In the presence of oxygen, most differentiated cells primarily catabolize glucose to carbon dioxide by oxidation of glycolytic pyruvate in the mitochondrial tricarboxylic acid (TCA) cycle (oxidative phosphorylation). On the other hand, cancer cells 'ferment' glucose into lactate (glycolysis) even when access to sufficient oxygen is available \[[@CR1]\]. This phenomenon is known as aerobic glycolysis or the Warburg effect \[[@CR1]\]. In terms of ATP production, oxidative phosphorylation is far more efficient than glycolysis, and it has long remained unclear why cancer cells selectively use aerobic glycolysis.

It is becoming more evident that actively proliferating cells consume glucose not only for ATP production, but also for the synthesis of nucleotides or fatty acids \[[@CR2]--[@CR4]\]. Cancer cells have a strong demand for replicating all of their components, and meet those needs by exploiting a specific branch of glycolysis \[[@CR5]\]. The pentose phosphate pathway (PPP) is a glycolysis shunt that produces the ribose and nicotinamide adenine dinucleotide phosphate required for the synthesis of macromolecules \[[@CR5], [@CR6]\].

Hepatocellular carcinoma (HCC) is a typical hypervascular tumor and appears to have good access to oxygen \[[@CR7]\]. However, the significance of aerobic glycolysis in HCC remains unclear. Fludeoxyglucose-positron emission tomography (FDG-PET) is a diagnostic imaging that exploits the excess glucose uptake by carcinoma cells over normal (differentiated) cells. While some studies have reported that FDG-PET is inferior to X-ray computed tomography in terms of accuracy \[[@CR8]\], others have indicated that FDG-PET is indeed useful for prognostication \[[@CR9]\]. Molecular analyses of HCC glycolysis have been performed using both microarray \[[@CR10]\] and immunohistochemistry \[[@CR11], [@CR12]\] techniques. Accumulating evidence suggests a possible causal role of aerobic glycolysis in HCC malignancy.

In the present study, we investigated the enzymes involved in glucose catabolism in HCC specimens. The synthesis of each enzyme protein was frequently altered, and such alteration was mostly consistent with the Warburg effect, that is, SDHA and SDHB were reduced and synthesis of PPP enzymes was augmented. Unexpectedly, ALDOA, an enzyme involved in mainstream glycolysis, was eliminated. The decrease of mitochondrial enzymes was not accompanied by HIF-1α activation, but augmented synthesis of PPP enzymes and loss of ALDOA were accompanied by nuclear accumulation of NRF2. Our findings confirm that HCC utilizes 'metabolic reprogramming' as a fundamental strategy for tumor growth by activating oncogenic signaling.

Methods {#Sec2}
=======

This study had the approval of the Institutional Review Board (provided ID number: 24089) on the basis of the Ethical Guidelines for Clinical Research of the Ministry of Health, Labour and Welfare in Japan (<http://www.mhlw.go.jp/seisakunitsuite/bunya/hokabunya/kenkyujigyou/i-kenkyu/index.html>).

Moreover, this study is registered with the UMIN Clinical Trials Registry (provided ID number: UMIN000011465).

Patients and tumor specimens {#Sec3}
----------------------------

Biospecimens were collected from patients newly diagnosed as having HCC that were undergoing surgical resection at Dokkyo Medical University Hospital. None of the patients had received prior treatment for their disease, including chemotherapy or radiotherapy. All cases were collected regardless of histologic grade, but those showing predominance of necrotic and inflammatory cells were excluded. Each tumor specimen had accompanying non-tumor tissue, which was cirrhosis in most cases. After pathological diagnosis, specimens from 45 patients were used for the present analysis, which was conducted under strict adherence to ethical guidelines.

Preparation of protein samples {#Sec4}
------------------------------

Protein samples were prepared either through subcellular fractionation or whole-cell lysis. To separate subcellular localized proteins, we used an NE-PER Nuclear Protein Extraction Kit (Thermo Scientific, Rockford, IL). Tissue specimens were weighed and minced with surgical scissors, and the minced tissue was immersed in hypotonic solution and homogenized in a Dounce homogenizer. After cell swelling/bursting and brief centrifugation, cytoplasmic (mitochondrial as well) and nuclear fractions were separated. Nuclear proteins were solubilized in RIPA buffer (25 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 % NP-40, 1 % sodium deoxycholate), and genomic DNA was fragmented by sonication (Bioruptor, Diagenode, Liege, Belgium). Proteins were denatured in lithium dodecyl sulfate (NuPAGE Sample Buffer, Life Technologies, Carlsbad, CA, USA) and reduced in 50 mM dithiothreitol. Starting with various specimen weights, and adding various amounts of reagents, the protein concentrations were adjusted to around 10 mg/ml (cytoplasm/mitochondria) or 5 mg/ml (nucleus). Successful fractionation was confirmed by immunoblotting for GAPDH (cytoplasm) or Histone H3 (nucleus). Alternatively, minced specimens were directly disrupted by sonication (Bioruptor) in denaturation buffer (7 M urea, 2 M thiourea, 2 % Triton X-100) and insoluble debris was removed by centrifugation.

SDS PAGE and immunoblotting {#Sec5}
---------------------------

Proteins were size-fractionated by electrophoresis in 8 or 12 % sodium dodecyl sulfate polyacrylamide gel, then wet-transferred to a PVDF membrane (Immobilon-P, Merck Millipore, Billerica, MA, USA). After blocking with 2 % skim milk or 5 % bovine serum albumin TBST (Tris/HCl pH 7.4, 150 mM NaCl, 0.1 % Tween20), the membranes were incubated with each respective primary antibody at 4 °C overnight. Non-specific binding was washed away with TBST and the protein-antibody complex was visualized using horseradish peroxidase-conjugated secondary antibody (\#7074 or 7076, Cell Signaling Technology, Beverly, MA, USA) and the luminescence reaction (ECL, ECL prime or ECL select, GE Healthcare, Little Chalfont, United Kingdom). Images were taken with a CCD camera and stored in the machine (LAS500, GE Healthcare).

Primary antibodies {#Sec6}
------------------

For the information about primary antibodies used in Western blotting, see the Supplemental Table 1.

Reverse transcription-polymerase chain reaction {#Sec7}
-----------------------------------------------

Total RNA was purified from biospecimens using the guanidine isothiocyanate method (Isogen Plus, Takara Bio Inc., Shiga, Japan). mRNA was subsequently reverse-transcribed to cDNA (Prime Script-RT, Takara Bio Inc.) and the amount of each mRNA was measured with a real-time PCR machine (ABI PRISM7000 realtime PCR system, Applied Biosystems, Foster City, CA). The TaqMan probes used are as follows: Eukaryotic *18S rRNA* (\#4333760F, Life Technologies), *ALDOA* (\#Hs00605108_g1, Applied Biosystems), *G6PD* (\#Hs00166169_m1, Applied Biosystems), *TKT* (\#Hs01115545_m1, Applied Biosystems), *SDHB* (\#Hs01042482-m1, Applied Biosystems) and *TKTL1* (\#Hs00202061_m1, Applied Biosystems). For *SDHA* amplification and detection, we utilized web-based qPCR design software (Universal Probe Assay Design Center, Roche Applied Science, Penzberg, Germany, <https://qpcr.probefinder.com/organism.jsp>). Universal probe \#70 was used for *SDHA* specific detection and the primer sequences of upper and lower primers are as follows: Forward 5′-TCCACTACATGACGGAGCAG-3′ and Reverse 5′-CCATCTTCAGTTCTGCTAAACG-3′. Size of SDHA product was 82 bp.

Data quantification and statistical analysis {#Sec8}
--------------------------------------------

Data from Western blotting was quantified with IQTL software (version8.1, GE healthcare). We calculated the relative abundance of protein as the ratio of tumor to non-tumor band intensity but the data of extremely low amounts were defined as 'under detection'. Some molecules were synthesized exclusively in tumor tissue (e.g., PKM2 or G6PD) and the data were presented as '−', '+', '++' or '+++'. The calculated ratio was subsequently normalized using GAPDH as a standard (ratio of target protein)/(ratio of GAPDH). Although we initially tested the feasibility of using GAPDH or β-actin as a standard molecule, GAPDH found to be superior (see Supplemental Table 2 for the standard deviation of each ratio). For nuclear proteins, Histone H3 served as a standard. Data from real-time RT-PCR was quantified using the 2^−ΔΔCt^ method \[[@CR13]\]. Dependencies between groups were analyzed using the chi-squared test, dividing each variable into two groups (e.g., PKM2 synthesized or not). Statistical analyses were performed using the SPSS statistical software package, version 20.0 (SPSS Inc., Chicago, IL, USA. Differences at *P* \< 0.05 were considered to be statistically significant.

Results {#Sec9}
=======

Inhibition of oxidative phosphorylation in HCC {#Sec10}
----------------------------------------------

First, we compared the synthesis of subunits of succinate dehydrogenase (SDH) complex that are functional in the TCA cycle. In comparison with their non-tumor tissue counterparts, synthesis of SDHA and SDHB proteins was reduced in the HCC tumor specimens (Fig. [1](#Fig1){ref-type="fig"}). Twenty-two (among 39 examined, 56 %) and 19 (among 40, 48 %) patients exhibited more than 40 % decrease for SDHA and SDHB, respectively. These data suggested that SDH activity was repressed and that the TCA cycle was arrested. To examine whether the decrease of SDH proteins was due to non-specific protein degradation, we checked isocitrate dehydrogenase (IDH), another enzyme involved in oxidative phosphorylation. IDH1 and IDH2 are localized to the cytoplasm and mitochondria, respectively, and we compared the synthesis of each protein between HCC and each respective non-tumor counterpart tissue sample. Although some patients exhibited decreased synthesis of IDH1 (11/37 = 30 %) and IDH2 (12/38 = 32 %), the frequency was not as remarkable as that observed for SDHA and SDHB.Fig. 1Frequent reduction of SDHA and SDHB synthesis in HCCs. Fifty μg of protein of whole-tissue lysate were loaded in each well, and Western blotting for TCA cycle enzymes was performed. Tumor/non-tumor paired samples were placed side by side. The band intensity was quantified with densitometry and the ratio between tumor/non-tumor were presented. GAPDH serves as an internal control. Eight representative specimens are shown

Pentose phosphate pathway is activated but mainstream glycolysis is inhibited in HCC {#Sec11}
------------------------------------------------------------------------------------

Next we examined the synthesis of the enzyme proteins glucose-6-phosphate dehydrogenase (G6PD) and transketolase (TKT) in HCC. G6PD and TKT are critical enzymes in the glycolysis shunt, the pentose phosphate pathway. We also examined the synthesis of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and aldolase (ALDOA), which are enzymes involved in mainstream glycolysis and therefore we expected them to serve as internal controls. Remarkably, synthesis of both G6PD and TKT was increased in HCCs relative to the non-tumor counterpart tissues (Fig. [2](#Fig2){ref-type="fig"}). Thirteen (among 29 examined, 45 %) and 21 (among 38, 55 %) patients exhibited this phenomenon for G6PD and TKT, respectively. On the other hand, synthesis of ALDOA was nearly eliminated (Fig. [2](#Fig2){ref-type="fig"}). The ratio of patients who had lost ALDOA relative to the total number of patients examined was 55 % (16/29). In contrast, synthesis of GAPDH was almost identical in tumor and non-tumor tissues (Fig. [2](#Fig2){ref-type="fig"}) in all of the patients examined (tumor/non-tumor: mean = 0.96, standard deviation = 0.27, *n* = 41).Fig. 2Frequently increased synthesis of G6PD and TKT, and loss of ALDOA synthesis, in HCCs. Fractionated cytoplasmic/mitochondrial proteins were loaded in each well and Western blotting for glycolysis/PPP enzymes was performed. Tumor/non-tumor paired samples were placed side by side. The band intensity was quantified with densitometry and the ratio between tumor/non-tumor was presented. β-actin serves as a loading control. Five representative specimens are shown

The hypoxia-inducible factor HIF-1α is not activated in HCCs {#Sec12}
------------------------------------------------------------

Next, we examined the synthesis and accumulation of HIF-1α protein in nuclear extracts from HCCs. However, we failed to detect the HIF-1α protein in most of the HCC patients (2/29 positive, data not shown). As a positive control, HIF-1α protein was easily detected in the lysate of Huh7 cells that had been incubated in a hypoxic chamber (O~2~ 1 %, 4 h, data not shown). Surgically resected specimens were exposed to ambient oxygen before preservation in a freezer, and the proteins were subsequently purified. To exclude the possibility that HIF-1α protein would have been degraded during sample preparation, we checked the events downstream of HIF-1α activation. When we compared the protein synthesis of cytochrome oxidase IV (COX4-1), a negative target of HIF-1α, 18 % of the patients (7/39) displayed a reduced level of COX4-1 protein (Fig. [3](#Fig3){ref-type="fig"}). We also examined the synthesis of PKM2 and LDHA, positive targets of HIF-1α. However, synthesis of the PKM2 protein was observed in 15 % (6/41) of the HCC patients (Fig. [3](#Fig3){ref-type="fig"}) and for LDHA, only 8 % of the patients (3/39) displayed augmented protein synthesis (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Occasional degradation of COX4-1, synthesis of PKM2 and augmented LDHA synthesis in HCCs. Fifty μg of protein of whole-tissue lysate were loaded in each well, and Western blotting for HIF-1 targets/modulators was performed. Tumor/non-tumor paired samples were placed side by side. The band intensity was quantified with densitometry and the ratio between tumor/non-tumor were presented. GAPDH serves as an internal control. Eight representative specimens are shown

Frequent nuclear accumulation of NRF2 protein in HCCs {#Sec13}
-----------------------------------------------------

Next, we examined the nuclear localization of a transcription factor NRF2. In contrast to HIF-1α, which was hardly detectable by the same method, NRF2 protein was detected in tumor tissue and occasionally in non-tumor tissue (Fig. [4](#Fig4){ref-type="fig"}). We used two different monoclonal antibodies recognizing distinct epitopes, but the data mostly overlapped (Fig. [4](#Fig4){ref-type="fig"}). The ratio of patients who possessed nuclear NRF2 relative to the total examined was 22/30 (73 % for NRF2 C-terminal) and 22/30 (77 % for phosphorylated S40 of NRF2). However, synthesis of KEAP1, an E3 uniquitin ligase against NRF2, varied (increase: 7/24, decrease: 9/24, unchanged: 8/24, data not shown).Fig. 4Frequent accumulation of NRF2 proteins in HCC nuclei. Fractionated nuclear proteins were loaded in each well, and Western blotting for NRF2 was performed. Tumor/non-tumor paired samples were placed side by side. The band intensity was quantified with densitometry and the ratio between tumor/non-tumor was presented. Histone H3 serves as an internal control. Five representative specimens are shown

Augmented synthesis of PPP proteins were correlated with mRNA induction {#Sec14}
-----------------------------------------------------------------------

Next, we measured mRNA transcription of genes that encode G6PD, TKT, ALDOA, SDHA or SDHB protein. As expected, gene transcription of *G6PD* was increased and correlated well with protein synthesis (Supplementary Fig. 1). The TKT protein is encoded by three distinct genes, *TKT*, *TKTL1* or *TKTL2*. Although *TKTL1* mRNA is known to be induced in some tumors (for review, see Riganti et al. \[[@CR14]\]), only trace amounts of the *TKTL1* mRNA were expressed, and we determined that the data were out of quantification range (data not shown). However, the *TKT* gene was abundantly expressed and further increased in tumor tissue (Supplementary Fig. 2), indicating that *G6PD* and *TKT* could be upregulated by a transcription factor, NRF2. On the other hand, transcription of the *ALDOA* gene was poorly correlated with protein synthesis (Supplementary Fig. 3). Fifty-eight percent of patients (7/12) displayed increased *ALDOA* expression, although most of these patients displayed loss of ALDOA protein (Supplementary Fig. 3). Thus, transcription of the *ALDOA* gene and the synthesis of ALDOA protein displayed an inverse relationship. We also examined the *SDHA* and *SDHB* gene transcription. However, neither *SDHA* (Supplementary Fig. 4) nor *SDHB* (Supplementary Fig. 5) had any apparent relationship between mRNA transcription and protein synthesis. Fifty percent (6/12) and 67 % (8/12) of patients displayed an inverse relationship with *SDHA* and *SDHB*, respectively.

SDH reduction did not correlate with hypoxia response, while increased synthesis of PPP enzymes correlated with activation of NRF2 {#Sec15}
----------------------------------------------------------------------------------------------------------------------------------

Finally, statistical analysis was performed to examine the dependencies among HIF-1α activation, and alteration of LDHA, PKM2, SDHA, SDHB and COX4-1 (Table [1](#Tab1){ref-type="table"}). HIF-1a activation was significantly correlated with PKM2 synthesis (*P* = 0.02). Synthesis of PKM2 was inversely correlated with decreased synthesis of SDHB (*P* = 0.033\*). Decreased COX4-1 synthesis was significantly correlated with decreased synthesis of SDHA and SDHB (*P* = 0.009 and *P* = 0.001, respectively), and decreased SDHA synthesis was significantly correlated with decreased SDHB synthesis (*P* \< 0.001).Table 1Dependencies between HIF-1α activation and alteration of glycolytic enzymeHIF-1αLDHAPKM2SDHASDHBCOX4-1HIF1αLDHA0.773PKM2**0.02**0.290SDHA0.7470.9200.067SDHB0.7270.234**0.033\*\<0.001**COX4-10.1970.9710.944**0.0090.001***Asterisk* denotes inverse correlation*Bold* number denotes statistically significantChi-square test, *P* \< 0.05*HIF1α* Hypoxia-induced factor 1α, *LDHA* Lactate dehydrogenase, *PKM2* Pyruvate kinase M2, SDH Succinate dehydrogenase

We next analyzed the dependencies between NRF2 activation (nuclear NRF2) and other protein alterations (Fig. [5](#Fig5){ref-type="fig"}). NRF2 activation was significantly correlated with G6PD synthesis (*P* = 0.044, Table [2](#Tab2){ref-type="table"}) and with TKT (*P* = 0.04, Table [2](#Tab2){ref-type="table"}), but not with other variables (data not shown).Fig. 5Relationships between NRF2 activation and G6PD or TKT increase. *Upper* Scatter plot of relative abundance of protein shows nuclear NRF2 (*y*-axis) and glycolysis enzymes (*x*-axis). Quantitative data are presented in log-scale (base = 2). *Lower* For patients who displayed undetectable NRF2 protein, protein levels of enzymes are shown as one-variable plots. *P* value is calculated with the chi-square testTable 2Dependencies between activation of NRF2 and pentose phosphate pathway enzymesVariableActivated NRF2C-terminal (*n* = 21)Not activated NRF2C-terminal (*n* = 8)*P*G6PD Activated142 Not activated760.044TKT Activated142 Not activated760.04Chi-squared test*G6PD* Glucose-6-phosphate dehydrogenase, *TKT* transketalase

Statistical analysis was also performed to compare the Western blotting data with various clinicolaboratory factors, such as tumor differentiation, number of tumors, tumor size, UICC TNM staging (7th edition), tumor markers (AFP, PIVKA-II), AST, ALT, Alb, CRP, PLT, and hepatitis viral infection (all the information are presented in Supplementary Table [2](#Tab2){ref-type="table"}). Increased expression of G6PD was significantly correlated with moderate or poor differentiation (*P* = 0.007). Augmented NRF2 activation was significantly correlated with invasive growth (*P* = 0.041). PIVKA-2 was significantly correlated with NRF2 activation and an increase of TKT (*P* = 0.004, *P* = 0.014). AFP was significantly correlated with an increase of G6PD and a decrease of IDH1 (*P* = 0.018, *P* = 0.015). ICGR15 was significantly correlated with IDH1 decrease (*P* = 0.008). Hepatitis virus C infection was significantly correlated with ALDOA decrease (*P* = 0.036, patients who had HCV vs. those who had HBV).

Discussion {#Sec16}
==========

In this study, we collected specimens of HCC from Japanese patients and examined the synthesis of enzymes involved in glucose metabolism. In comparison to other solid tumors, the tissue composition of HCC is relatively uniform in both the tumor and non-tumor components. Data obtained from subcellular fractionation and Western blotting could reflect the metabolic status of HCC in situ. Our present findings are mostly consistent with Warburg's original report, although we discovered some unexpected phenomena as well.

Overall, the liver is a hypervascular organ, and thus HCC is likely to have a good oxygen supply during tumor formation. Nevertheless, HCC intensively induces angiogenesis and grows into an apparently vascular-rich tumor. One possible explanation is that HIF-1 is activated under normoxic conditions and induces vascular endothelial growth factor. We observed that synthesis of SDHA and SDHB was frequently reduced (22/39 and 19/40, respectively) in HCCs (Fig. [1](#Fig1){ref-type="fig"}). SDHB is a tumor suppressor of familial paraganglioma or pheochromocytoma \[[@CR15], [@CR16]\], and loss of its function leads to succinate accumulation \[[@CR17]\]. Succinate is a substrate of SDH and its accumulation results in inhibition of prolyl hydroxylase and subsequent stabilization of HIF-1α \[[@CR17]\]. Activation of HIF-1α, in turn, induces LONP1, a protease that degrades mitochondrial protein cytochrome oxidase IV (COX4-1) and inhibits oxidative phosphorylation \[[@CR18]\]. Moreover, HIF-1α activation enhances *LDHA* gene expression \[[@CR3]\], and the cooperative activation of HIF-1α and PKM2 is the driving force of aerobic glycolysis \[[@CR19]\]. Thus, SDH function and HIF-1 are closely related to each other, and we had expected that SDHA/SDHB reduction would be accompanied by HIF-1 activation. However, we concluded that this was not the case, based on certain items of evidence. First, HIF-1α protein was detected in only 7 % of HCC patients (2/29). Second, augmented synthesis of a transcription target (LDHA) was also a rare event in HCCs (8 % = 3/39). Third, although activation of PKM2 was occasional (15 % = 6/41), it was inversely correlated with SDHA/SDHB reduction (Table 1). Indeed, statistical analysis indicated that alteration of COX4-1 was correlated with SDHA/SDHB decrease (Table 1), and this specific variable could partly explain the decrease of SDH (mitochondrial remodeling). Other variables (HIF-1α, PKM2 and LDHA), however, were not positively correlated with SDHA/SDHB decrease. It is generally accepted that hypoxia-inducible factors play crucial roles in hepatocellular carcinogenesis \[[@CR20]\]. Previous studies used immunohistochemistry to detect HIF-1α in HCC specimens \[[@CR21]--[@CR23]\]. We cannot exclude the possibility that HIF-1α was activated below the detection range of our present method, or that other HIF proteins were activated instead \[[@CR24]\]. However, we speculate that activation of HIF-1α is not a predominant factor of HCCs in Japanese patients.

The accumulation of NRF2 in HCC nuclei (73 % = 22/30 for NRF2 C-terminal and 77 % = 23/30 for phosphorylated S40 of NRF2) was another major discovery. Recently, comprehensive exome sequencing of HCC has been carried out, and frequently mutated genes have been reported \[[@CR25]\]. Among four newly identified genes, *NFE2L2* encodes NRF2 protein \[[@CR25]\]. NRF2 was originally identified as a transcription factor that responds to various stress signals, such as oxidative stress \[[@CR26]\]. Upon activation by such stresses, NRF2 induces a series of detoxifying enzymes and antioxidant genes \[[@CR26]\]. Under normal conditions, E3 ubiquitin ligase KEAP1 maintains NRF2 at a very low level through the ubiquitin--proteasome degradation system \[[@CR27], [@CR28]\]. In addition to the well-known target genes of NRF2, Motohashi and colleagues have identified PPP enzymes (G6PD, PGD, TKT and TALDO1) as novel targets of NRF2 \[[@CR29]\]. Our findings are consistent with their report: NRF2 translocation to nuclei involved an increase of G6PD and TKT (Figs. [2](#Fig2){ref-type="fig"}, [4](#Fig4){ref-type="fig"}). Interestingly, their study verified that oncogenic PI3 kinase signaling augments Nrf2 translocation to murine hepatocyte nuclei \[[@CR29]\]. We also observed occasional NRF2 accumulation in nuclei of non-tumor cirrhotic tissue, but the amount was mostly higher in tumor tissue (77 % = 17/22 for NRF2 C-terminal or 70 % = 16/23 for phosphorylated S40 of NRF2). These data suggest that the oncogenic signal is needed to augment NRF2 translocation in HCCs.

Constitutive stabilization/activation of NRF2 protein is a prognostic indicator in some cancers \[[@CR30]--[@CR32]\]. Several different mechanisms can explain NRF2 activation: (1) point mutation in the *KEAP1* or *NFE2L2* gene \[[@CR30], [@CR31], [@CR33], [@CR34]\]; (2) synthesis of an inhibitor of KEAP1-NRF2 interaction \[[@CR35]--[@CR37]\]; (3) promoter methylation and silencing of the *KEAP1* gene \[[@CR38], [@CR39]\]; (4) succination of KEAP1 and subsequent dissociation of KEAP1-NRF2 interaction \[[@CR40]\]. Two studies have reported that the rate of point mutation in the *NFE2L2* gene is 6.4 % \[[@CR25]\] and in the *KEAP1* gene is 8.9 % \[[@CR41]\]. Although we did not carry out mutational screening in this series of Japanese HCC cases, the modest frequency of point mutation is unlikely to explain the high incidence of nuclear translocation of NRF2 (Supplementary Table 2). Alternatively, chronic inflammation results in deregulation of autophagy, leading to accumulation of an inhibitor of KEAP1-NRF2 interaction \[[@CR36], [@CR42]\]. The possibility that increased succinate caused by loss of SDHA/SDHB might result in KEAP1 succination is also intriguing \[[@CR40]\].

Unexpectedly, we observed that ALDOA protein was frequently eliminated in HCCs (Fig. [2](#Fig2){ref-type="fig"}). Three isozymes are encoded by three different genes: *ALDOA*, *ALDOB* and *ALDOC*. It has been reported that the expression of *ALDOB* mRNA is reduced in HCCs \[[@CR43]\], whereas that of *ALDOA* mRNA is increased \[[@CR44]\], thus fitting the conventional concept of enhanced glycolysis. Indeed, as for mRNA expression, we confirmed that this was the case in Japanese HCC specimens (Supplementary Fig. 3). Nevertheless, the synthesis of ALDOA protein did not correlate with mRNA expression (Supplementary Fig. 3). Of note, the band of ALDOA was migrated more slowly in tumor specimens compared to non-tumor counterparts (Fig. [2](#Fig2){ref-type="fig"}). It is possible that ALDOA protein is constantly degraded due to post-translational modification, such as ubiquitination. Aldolase catalyses a reversible aldol reaction utilizing not only fructose 1,6-bisphosphate, but also sedoheptulose 1,7-bisphosphate as substrates. The latter is located in the non-oxidative arm of PPP and this specific branch is known to be regulated by oncogenic signaling \[[@CR45]\]. Future studies will need to clarify whether ALDOA is simply a bystander or an active driver of carcinogenesis.

There are a couple of differences between the classical definition of the Warburg effect and our present observations (Supplementary Fig. 6). First, increased expression of LDHA (an enzyme for lactate production) was a rare event (8 % = 3/39). Second, synthesis of PKM2 (a driver of aerobic glycolysis) was occasional (15 % = 6/41), but inversely correlated with a reduction of SDH proteins. Third, ALDOA (an enzyme for mainstream glycolysis) was frequently eliminated (55 % = 16/29). Currently, we are extending our analysis to other gastrointestinal tumors such as colorectal carcinomas (CRCs). In contrast to HCCs, CRCs frequently synthesized PKM2 protein and increased ALDOA protein (Supplementary Fig. 6, N. Shibuya, K. Inoue and K. Kubota, manuscript in preparation). Increased PPP enzymes, however, were observed in CRCs as well (Supplementary Fig. 6). Data indicate that the Warburg effect, at least in HCC, does not fit the stereotypic form originally proposed. If HCC does not augment mainstream glycolysis, the net glusose uptake of tumor cells could be similar to those of surrounding hepatocytes. Although further evidence is needed, this could be the reason why the usefulness of FDG-PET is relatively low compared to other tumors (difficult to distinguish the change of FDG uptake).

Lastly, but not least, metabolic reprogramming seems to be a fundamental survival strategy of cancer cells \[[@CR46]\]. In the near future, a more comprehensive understanding of aerobic glycolysis may lead to the design of novel therapeutic strategies for HCC.
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